News

As per the terms of the agreement, Endo is expected to retain all rights to the molecules developed, while Syngene will receive research fees, milestone payments and success

Cadence submitted its first new drug application in May 2009 for intravenous acetaminophen, its investigational product candidate. It has partnered with ISI to identify the best delivery model

The company said that the CE marking certifies that the two products have met the European Union (EU) health and safety standards and are approved for sale in

In a previously conducted Phase 1B, PMX-60056 demonstrated safety and efficacy in reversing heparin in healthy subjects. PMX-60056, one of PolyMedix’s lead compounds, is designed as a small

AP Pharma’s APF530 contains the 5-HT3 antagonist, granisetron, formulated in the company’s proprietary Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days

Cytokinetics claimed that CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company’s skeletal muscle contractility program. CK-2017357

BioGaia already has agreements with Ferring Pharmaceuticals covering some ten countries in Latin America, where Mexico was the first country to launch the products. In Argentina the regulatory

The trial will assess the safety, tolerability and efficacy of Stemedica’s high potency allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke. The

Synergy Pharma said that SP-304 is a member of a new class of non-systemic drugs for treatment of chronic constipation (CC), irritable bowel syndrome with constipation (IBS-C) and